Literature DB >> 7529292

Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice.

E A Reap1, D Leslie, M Abrahams, R A Eisenberg, P L Cohen.   

Abstract

The murine gene lpr encodes an aberrant form of the apoptosis-inducing receptor Fas. The gene gld, which causes an autoimmune syndrome phenotypically identical to that caused by lpr, encodes a mutant Fas ligand. Because the lpr gene must be expressed in both T and B cells to produce autoimmune disease, it might be anticipated that apoptosis abnormalities would be present in both. Therefore, we quantitated apoptosis in T and B cells from lpr, gld, and normal mice in a short-term in vitro culture system. Freshly isolated spleen cells from normal, lpr, or gld mice showed little or no apoptosis as assessed by quantitative DNA flow cytometry. However, after overnight culture, both T and B cells showed substantial spontaneous apoptosis. Such apoptosis increased strikingly with age in normal but not in autoimmune B cells. CD23low B cells, which are prominent in lpr and gld mice, were particularly notable for high levels of programmed cell death in normal mice. The apoptosis caused by the gld defect could not be corrected by coculture with normal spleen cells. The persistence with age of low levels of B cell apoptosis in lpr and gld mice presumably reflects deficient Fas/Fas ligand interactions. The further localization of the B cell apoptosis defect to the unusual CD23low B cells, which accumulate in lpr and gld mice, adds to the evidence that these cells may be of critical importance to autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529292

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L).

Authors:  D C Huang; M Hahne; M Schroeter; K Frei; A Fontana; A Villunger; K Newton; J Tschopp; A Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions.

Authors:  E A Reap; K Roof; K Maynor; M Borrero; J Booker; P L Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

3.  CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease.

Authors:  K G Smith; A Strasser; D L Vaux
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

4.  Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs.

Authors:  G Strauss; W Osen; K-M Debatin
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

5.  Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes.

Authors:  C Mohan; E Alas; L Morel; P Yang; E K Wakeland
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

6.  Nitric oxide and dihydrolipoic acid modulate the activity of caspase 3 in HepG2 cells.

Authors:  Rajib Sengupta; Timothy R Billiar; James L Atkins; Valerian E Kagan; Detcho A Stoyanovsky
Journal:  FEBS Lett       Date:  2009-10-12       Impact factor: 4.124

Review 7.  Programmed cell death: the influence of CD40, CD95 (Fas or Apo-I) and their ligands.

Authors:  N Laytragoon-Lewin
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

Review 8.  Murine models of systemic lupus erythematosus.

Authors:  Daniel Perry; Allison Sang; Yiming Yin; Ying-Yi Zheng; Laurence Morel
Journal:  J Biomed Biotechnol       Date:  2011-02-14

Review 9.  Fas and the art of lymphocyte maintenance.

Authors:  M J Lenardo
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

10.  Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand.

Authors:  T Renno; M Hahne; J Tschopp; H R MacDonald
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.